Pre-made Brolucizumab benchmark antibody ( scFv, anti-VEGFA therapeutic antibody, Anti-VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-083
Pre-Made Brolucizumab biosimilar, scFv, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Brolucizumab, sold under the trade name Beovu, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Brolucizumab biosimilar, scFv, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Approved||Wet age-related macular degeneration|
|Conditions Active||Diabetic macular oedema;Retinal vein occlusion;Diabetic retinopathy|